logo

For the Inventor, By the Inventor

Brussels, Belgium

Ucb Biopharma Sprl


USPTO Granted Patents = 139

% Expired Patents = 26.6



Trademarks = 11

Forward Citations = 813

Loading Chart...
Loading Chart...

242 inventors (with patents filed for the assignee):

goldMedal Martin John McLoughlin (23 out of 31 patents)

silverMedal Victoria Elizabeth Jackson (22 out of 22 patents)

bronzeMedal Boris Kroeplien (20 out of 26 patents)

4.  Kerry Louise Tyson (19 out of 42 patents)

5.  John Robert Porter (17 out of 67 patents)

6.  Ralph Adams (15 out of 41 patents)

7.  Michael James David Heald (15 out of 21 patents)

8.  David Paul Humphreys (14 out of 46 patents)

9.  Alastair David Griffiths Lawson (13 out of 37 patents)

10.  Daniel Christopher Brookings (13 out of 37 patents)

11.  Helene Margaret Finney (12 out of 24 patents)

12.  Ilario Melzi (12 out of 33 patents)

13.  Eric Freitag (12 out of 42 patents)

14.  Kevin Richard Lozeau (12 out of 18 patents)

15.  Terence Seward Baker (11 out of 36 patents)


Core Competencies:
Monoclonal Antibodies
Autoinjector Devices
Protein Manufacture
Tau-Binding Antibodies
Bispecific Antibodies
Anti-FcRn Antibodies
Multispecific Antibodies
Neutralising Antibodies
Crystalline Forms
Therapeutic Systems
Inflammation Treatment
Kinase Inhibitors

139 patents:

1. 12747288 - TAU-BINDING ANTIBODIES (2026-09-29),
2. 11517676 - Assembly for an autoinjector device (2022-12-06),
3. 11331438 - Cap for an injector (2022-05-17),
4. 11324896 - Cap for an injector (2022-05-10),
5. 11220547 - Antibodies specific to FCRN (2022-01-11),
6. 11059820 - Crystalline forms of seletalisib (2021-07-13),
7. 10889640 - Tau-binding antibodies (2021-01-12),
8. 10829565 - Method for increasing the percentage of monomeric antibody Fab-dsFv multimeric species (2020-11-10),
9. 10828366 - Method of monomerisation of recombinant antibody molecules (2020-11-10),
10. 10774152 - Molecules with specificity for CD45 and CD79 (2020-09-15),
11. 10759844 - Disulfide stabilised antibodies and fragments thereof (2020-09-01),
12. 10752676 - Neutralising antibodies to the major exotoxins TCDA and TCDB of (2020-08-25),
13. 10661023 - Systems and methods for administering medication (2020-05-26),
14. 10639424 - Auto-injector and drive unit therefor (2020-05-05),
15. 10639423 - Auto-injector and drive unit therefor (2020-05-05),
Company Overview
Ucb Biopharma Sprl, headquartered in Brussels, Belgium, is a biopharmaceutical company specializing in the development and manufacture of monoclonal antibodies. The organization focuses on innovative therapies that target complex diseases, leveraging advanced technologies in protein manufacture and antibody engineering. Ucb's expertise encompasses a range of core technology topics, including tau-binding antibodies, bispecific antibodies, and autoinjector devices, aimed at improving patient outcomes through precision medicine.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Ucb Biopharma Sprl USPTO Patent Assignee Logo
139 Patents

#10 in Brussels

#34 in Belgium

#5,821 in the World

Brussels, BE
Brussels, Belgium

Ucb Biopharma Sprl

Forward Citations = 813

242 inventors:

goldMedal Martin John McLoughlin (23 out of 31 patents)

silverMedal Victoria Elizabeth Jackson (22 out of 22 patents)

bronzeMedal Boris Kroeplien (20 out of 26 patents)

4.  Kerry Louise Tyson (19 out of 42 patents)

5.  John Robert Porter (17 out of 67 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ucb Biopharma Sprl. Retrieved from https://idiyas.com/company/ucb-biopharma-sprl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…